Virtual Reality for Non-cardiac Chest Pain
This study is exploring whether virtual reality (VR) therapy can help improve symptoms for people experiencing non-cardiac chest pain (NCCP). NCCP is chest pain that isn't caused by heart problems. The study aims to see if VR is a practical and helpful treatment option. Researchers will look at how willing people are to join, how well they stick with the VR therapy, and if it helps with pain, anxiety, and quality of life. You may be able to join if you are 18 or older, have NCCP symptoms, and have had a heart evaluation that ruled out cardiac issues. The study is currently unclear on its recruitment status and plans to enroll 10 participants.
- Study design
- This is an interventional study with a planned enrollment of 10 participants. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints, such as changes in GERD (Gastroesophageal Reflux Disease) symptoms and quality of life, are measured at Week 2.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Virtual Reality for Non-cardiac Chest Pain
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Andree Koop, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Measure changes in GERD symptoms using the GERDQ questionnareWeek 2
Gastroesophageal reflux disease (GERD) questionnaire (GerdQ) is a 6-item questionnaire (scale from 0 to 18) that measures heartburn, regurgitation, abdominal pain, nausea, sleep disorders, and the over-the-counter (OTC) drugs use. The score predicts the likelihood of GERD, with a score between 11-18 suggesting 89% or greater likelihood.
- Measure changes in GERD quality of life using the GERD-HRQL questionnaireWeek 2
GERD-HRQL- Gastroesophageal reflux disease (GERD) - Health Related Quality of Life (HRQL) The scale has 15 items, which focus on heartburn symptoms, dysphagia, medication effects and health condition. Each item is scored from 0 to 5 (maximum score 75), with a higher score indicating a better QOL
- Measure changes in esophageal symptom specific anxiety using the EHAS questionnaireWeek 2
The esophageal hypervigilance and anxiety scale (EHAS) The EHAS is a 15-item measure with two factors evaluating esophageal hypervigilance and symptom specific anxiety scored on a 0-4 Likert scale. Items are summed to yield a total score ranging from 0 - 60 (Greater hypervigilance/anxiety).
- Measure changes in GI symptom severity using the PAGI-SYM questionnaireWeek 2
Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) The PAGI-SYM includes 6 subscales ranging from 0 (none) to 5 (very severe): heartburn/regurgitation, fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain.
- Measure changes in GI related patient assessment of quality of life using PAGI-QOLWeek 2
Patient Assessment of Gastrointestinal Disorders-Quality of Life (PAGI-QOL) The PAGI-QOL Is an instrument scoring 30 factors each from 0 (none of the time) to 5 (all of the time). Symptoms are assessed over a 2 week period and include the 5 domains daily activities, clothing, diet and food habits, psychological well-being/distress, and relationships.